Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
New asthma inhaler propellant effective, but costlier
April 11th, 2007
A common asthma inhaler powered by a new propellant is safe and effective but could come at nearly triple the cost to consumers until a generic version hits the market, according to a review in the New England Journal of Medicine. Conducted by two university professors and a director for the Food and Drug Administration, the review examines the consequences of switching to hydrofluoroalkane, which is replacing chlorofluorocarbon, or CFC, as a key ingredient in albuterol inhalers designed to relieve asthma. The FDA has ruled that U.S. sales of CFC albuterol inhalers be prohibited after 2008. About 52 million prescriptions are filled for albuterol each...
Source: Immunotherapy Weekly (2007-04-11)
|
